GlassScriptPhysician profile
Dana E Malloy
NPI 1679719819
$4,837.96
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,866 · 2022: $1,360 · 2023: $1,360 · 2024: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,611.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $476.08 | 2021-2023 | Farxiga, Breztri |
| Lilly USA, LLC | $453.16 | 2021-2024 | Mounjaro |
| Abbvie INC. | $386.66 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $385.35 | 2021-2024 | |
| Novo Nordisk INC | $356.57 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Insmed, INC. | $217.13 | 2021-2023 | Arikayce |
| Corcept Therapeutics | $171.28 | 2021-2023 | Korlym |
| Pfizer INC. | $169.22 | 2021-2023 | |
| Melinta Therapeutics, LLC | $166.72 | 2021-2023 | Vabomere, Kimyrsa, Rezzayo |
| Xeris Pharmaceuticals, INC. | $157.13 | 2021-2023 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $146.12 | 2021-2023 | Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.41 | 2021-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $132.77 | 2021-2023 | Verquvo, Steglatro, Belsomra |
| Amgen INC. | $132.18 | 2021-2024 | Repatha, Otezla, Evenity |
| Insulet Corporation | $111.86 | 2022-2024 | Omnipod |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Malloy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.